An U.S. Food and Drug Administration (FDA)-advisory panel has voted to strip Avastin’s indication for metastatic breast cancer because the drug is not effective for this indication. Final action will be taken by the FDA. Read more here.
© 2020 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder